CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Comparing Palliative Stereotactic Body Radiotherapy vs. Palliative Standard Radiotherapy in Patients with Advanced Head and Neck Cancer
LND101 for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced Melanoma
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab or Botensilimab Alone vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
CCTG is excited to be hosting the new Clinical Research Associate (CRA) lunch and learn training program. This program is intended to provide CRAs with practical information and training around the activation and conduct of CCTG studies.
Biomarkers to Inform Prognosis and Treatment for Unresectable or Metastatic GEP-NENs
PM2 CAN-IMPACT-IO is a unique national initiative to measure, predict and assess cancer treatment outcomes in patients who have been treated with immunotherapy.
Patients on CCTG clinical trials who consent to CAN-IMPACT-IO will have blood and tumour tissue biopsy taken to analyses to look for features that correlate with benefit or lack of benefit to immunotherapy.
The HN13 clinical trial has recently opened in Canada and will explore a new radiotherapy technique called stereotactic body radiotherapy (SBRT) to treat patients with advanced head and neck cancer. Researchers want to know if SBRT offers better cancer and symptom control than the standard radiotherapy (RT).
CCTG welcomes new Patient Representative Sally Nystrom who will be supporting the CCTG Melanoma Committee
